Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study. (October 2022)

• Record Type: Journal Article
• Authors: Teeyapun, Nattaya; Luangdilok, Sutima; Pakvisal, Nussara; Sainamthip, Panot; Mingmalairak, Siyamol; Poovorawan, Nattaya; Sitthideatphaiboon, Piyada; Parinyanitikul, Napa; Sriuranpong, Virote; Namkanisorn, Teerayuth; Inthasuwan, Pratchaya; Angspatt, Pattama; Wongchanapat, Ploytuangporn; Bamrungnam, Akradach; Leeleakpai, Nutchanok; Uttha, Sutheera; Jaichum, Supaporn; Kongkaew, Peerawich; Suksanong, Chayanin; Veranitinun, Rattiya; Prasomphol, Ampai; Sartsuk, Chada; Patcharajutanon, Cheeraporn; Preaprang, Supreeya; Choengsamor, Hathairat; Phongwan, Rungthong; Preeyasaksa, Charoenpit; Phaibulvatanapong, Ekkamol; Suntronwong, Nungruthai; Yorsaeng, Ritthideach; Vichaiwattana, Preeyaporn; Wanlapakorn, Nasamon; Kerr, Stephen J.; Poovorawan, Yong; Wanchaijiraboon, Passakorn; Tanasanvimon, Suebpong;
• Is Part Of: EClinicalMedicine. Volume 52(2022)
• Publication Date: 2022-10
• Subjects: ChAdOx1-nCoV-19 vaccine -- Immunogenicity -- Cancer patients -- Cancer treatments; Medicine -- Research -- Periodicals; Medical policy -- Periodicals; Clinical Medicine; Health Policy; Public Health; Medical policy; Medicine -- Research; Periodical; Electronic journals; Periodicals; 613
• DOI: 10.1016/j.eclinm.2022.101608
• Languages: English
• ISSNs: 2589-5370

Abstract

Summary: Background: Limited data exists regarding the efficacy of ChAdOx1-nCoV-19 vaccine against Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in solid cancer patients. We aimed to assess the immunogenicity of the ChAdOx1-nCoV-19 vaccine and the impact of different anticancer therapies for solid malignancies on immune response. Methods: This prospective, longitudinal observational study of immunogenicity following ChAdOx1-nCoV-19 vaccination among 385 solid cancer patients on active cancer treatment was conducted in two oncology centers. Participants received the first dose between June 18 and July 27, 2021 and the second dose at 8-10 weeks later. Blood samples were evaluated for total immunoglobulins against the receptor-binding of SARS-CoV-2 spike protein (anti-RBD total-Ig) before, and 4-week after the first- and second-doses. The primary endpoint was the geometric mean titers (GMT) of antibody among solid cancer patients compared to healthy controls and the impact of different cancer treatment types. Findings: Among solid cancer patients, the antibody level increased more slowly to significantly lower levels than achieved in healthy controls. The GMT at 4-weeks post-vaccination in cancer vs. healthy were 224.5 U/ml (95%CI 176.4–285.6) vs. 877.1 U/ml (95%CI 763.5–1008), p <0.0001), respectively. For different types of cancer treatments, chemotherapy agents, especially anthracyclines (GMR 0.004; 95%CI 0.002–0.008), paclitaxel (GMR 0.268; 95%CI 0.123–0.581), oxaliplatin (GMR 0.340; 95%CI 0.165–0.484), and immunotherapy (GMR 0.203; 95%CI 0.109–0.381) showed significantly lower antibody response. Anti-HER2, endocrine therapy and 5-fluouracil or gemcitabine, however, had less impact on the immune response. Interpretation: Suboptimal and heterogeneous immunologic responses were observed in cancer patients being treated with different systemic treatments. Immunotherapy or chemotherapy significantly suppressed the antibody response. Funding: Quality Improvement Fund, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Center of Excellence in Clinical Virology at Chulalongkorn University and Chulalongkorn Medical Oncology Research Fund